Optimal Administration of Allopurinol in Dialysis Patients

Status Completed

Clinical Trial Summary

Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some evidence shows that it is also dialyzable. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication.

Clinical Trial Description

Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. A study has shown an incidence of fifteen percent of gout in the first five years spent in dialysis and it was associated with an increased mortality. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some studies from the early 1960s demonstrated that it is also dialyzable. At the moment, we do not have strong evidence of the optimal dosage of allopurinol with modern techniques of dialysis. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication. Dosage of uric acid will be performed to assess the efficacy of the intervention. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02477488
Study type	Interventional
Source	Maisonneuve-Rosemont Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	June 2015
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05990660` - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery	N/A
Recruiting	`NCT04096547` - Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Completed	`NCT04024332` - Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects	Phase 1
Completed	`NCT02849964` - Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions	N/A
Active, not recruiting	`NCT03672110` - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen	Phase 3
Completed	`NCT01462136` - PK Study of ACHN-490 Injection in Renally Impaired Subjects	Phase 1
Completed	`NCT01407874` - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2
Completed	`NCT01172431` - Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency	Phase 4
Completed	`NCT01545531` - Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance	N/A
Completed	`NCT00765830` - Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)	Phase 3
Completed	`NCT00770081` - Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)	Phase 3
Terminated	`NCT00338455` - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC	Phase 2
Completed	`NCT00159614` - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment	Phase 2
Completed	`NCT02894905` - A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335	Phase 1
Completed	`NCT02894385` - Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)	Phase 1
Active, not recruiting	`NCT04876963` - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Completed	`NCT03235375` - A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects	Phase 1
Withdrawn	`NCT03329612` - Remote Ischemic Preconditioning in ACS Patients	N/A
Recruiting	`NCT02578784` - DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis	N/A